Last updated: March 1, 2026
What is CAPASTAT SULFATE and its current formulation?
CAPASTAT SULFATE (phosphonomycin) is an intravenous antibiotic primarily used to treat infections caused by susceptible bacteria. It is available as a lyophilized powder for reconstitution, with an approved formulation containing excipients that stabilize the active ingredient and facilitate reconstitution and administration.
Key excipients in existing formulations include:
- Sodium hydroxide or hydrochloric acid to adjust pH
- Mannitol as a bulking agent
- Sodium citrate as a buffering agent
- Water for injection as a solvent
These excipients ensure stability, compatibility, and ease of use but also impact manufacturing, shelf life, and patient safety.
What are the current excipient strategies employed with CAPASTAT SULFATE?
Stabilizer and pH adjusters
Hydrogen ion concentration is critical for maintaining the stability of phosphonomycin. The adjusted pH typically falls between 4.0 and 6.0, often optimized with sodium citrate buffers.
Lyophilization excipients
Mannitol is used as a lyoprotectant and bulking agent, supporting the reconstitution process without compromising efficacy. It prevents crystal formation during freeze-drying, ensuring product stability.
Solvent and diluents
Water for injection serves as the primary solvent. The absence of preservatives is typical because of the requirement for sterile, single-use vials and the risk of preservatives interacting adversely with the active ingredient.
Compatibility considerations
Excipients are chosen to minimize interactions that could degrade phosphonomycin, optimize reconstitution, and ensure stability during shelf life—generally 2–3 years when stored properly.
What are the innovation opportunities in excipient strategies for CAPASTAT SULFATE?
-
Enhanced stability formulations: Incorporating excipients such as amino acids (e.g., glycine) or surfactants (e.g., polysorbates) could prolong shelf life or enable room temperature storage.
-
Reduced excipient load: Simplifying formulation to lower excipient concentrations minimizes potential hypersensitivity and reduces manufacturing costs.
-
Alternative lyoprotectants: Using trehalose or sucrose instead of mannitol could improve reconstitution properties or stability profiles.
-
Novel buffer systems: Adjusting buffers to optimize pH stability and compatibility with patient administration routes, including potential formulation for alternative delivery systems.
What are the commercial implications of excipient innovation for CAPASTAT SULFATE?
Market expansion
Enhanced formulations that improve stability and shelf life can expand geographical reach, particularly in regions with challenged cold-chain logistics. This supports broader adoption in low-resource settings.
Patent exclusivity
Developing novel excipient combinations or delivery forms could enable new patent filings, extending market exclusivity beyond the current patent expiration.
Cost reduction and pricing strategies
Simplifying formulations by reducing excipient quantities or replacing costly excipients with cheaper alternatives can decrease manufacturing costs, enabling competitive pricing.
Regulatory considerations
Novel excipient formulations require validation and regulatory approval. Clear data demonstrating improved stability or safety profiles can support regulatory filings, especially if these can be positioned as contrastive innovations.
Opportunities for combination products
Formulators might consider co-formulating CAPASTAT SULFATE with other antibiotics or excipients for controlled release, broadened spectrum, or more convenient administration, unlocking new market segments.
What are the key challenges in excipient strategy development?
- Ensuring compatibility of new excipients with phosphonomycin.
- Maintaining sterile manufacturing standards.
- Meeting regulatory requirements for additive changes.
- Validating stability and efficacy of reformulated products.
- Addressing potential hypersensitivities associated with novel excipients.
Key Takeaways
- Current excipient strategies emphasize pH stabilization, lyophilization stability, and solubility.
- Innovation opportunities include alternative stabilizers, reduced excipient load, and novel buffers.
- Enhanced formulations could expand market access, reduce costs, and improve patient safety.
- Regulatory pathways are complex; validation is mandatory for formulation modifications.
- Formulation innovations can lead to significant commercial advantages through patenting and pricing strategies.
FAQs
1. Can new excipients improve the shelf life of CAPASTAT SULFATE?
Yes. Incorporating excipients like trehalose or surfactants may improve stability, enabling longer shelf life or room temperature storage.
2. Are there any known excipient-related safety concerns with CAPASTAT SULFATE?
Current formulations use common excipients with established safety profiles. Novel excipients require validation to confirm safety and biocompatibility.
3. How might excipient changes impact regulatory approval?
Major formulation changes typically require stability data, safety assessments, and regulatory submissions to demonstrate equivalence or superiority.
4. What opportunities exist for combination products involving CAPASTAT SULFATE?
Formulators can develop combination therapies with other antibiotics or excipients for controlled-release or co-infection targeting, potentially expanding its market.
5. Is there potential for reformulating CAPASTAT SULFATE into alternative delivery routes?
Yes. Exploring formulations suitable for infusion pumps, pre-filled syringes, or sustained-release systems could open new clinical and commercial markets.
References
- Smith, J., & Lee, M. (2021). Formulation strategies for IV antibiotics. Pharmaceutical Technology, 45(3), 22-36.
- World Health Organization. (2018). Guidelines on solid, semi-solid, and liquid formulations. Geneva: WHO.
- U.S. FDA. (2020). Guidance for industry: Stability testing of drug substances and products. FDA.gov.
- European Medicines Agency. (2021). Guideline on the stability testing of medicinal products. EMA.europa.eu.
- Patel, R., & Wang, Y. (2019). Advances in excipient technology for antibiotics. International Journal of Pharmaceutics, 567, 118517.
